U.S. Contraceptives Market Size & Share 2025 - 2034

U.S. Contraceptives Market Size

The U.S. contraceptives market was valued at USD 7.3 billion in 2024. The market is expected to reach from USD 7.6 billion in 2025 to USD 13.5 billion in 2034, growing at a CAGR of 6.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The high market growth is attributed to the increasing rate of unintended pregnancies, technological advancements in contraceptive options, growing preference for preventive healthcare, and rising awareness of family planning and sexual health, among other contributing factors.
 

Contraceptives are medical methods, devices, or drugs used to prevent pregnancy by interfering with fertilization or implantation. This category contains systemic and local hormonal methods (pills, implants, injectable contraceptives, patches, IUDs), mechanical barriers (condoms, diaphragms), and rescue contraceptive pills. Beyond pregnancy prevention, select products also modulate menstrual regularity and alleviate diverse gynecological disorders.
 

Leading players in the contraceptives market include Bayer, Church & Dwight, Cooper, Organon, and Pfizer. These companies maintain their competitive edge through continuous product innovation, market presence, and significant investments in research and development.
 

The U.S. recorded approximately 3.7 million pregnancies in 2021, with 45% being unplanned according to the Centers for Disease Control and Prevention (CDC). Healthcare organizations actively promote contraceptive methods to reduce the USD 5.5 billion annual maternal and child healthcare expenses reported by the U.S. Department of Health and Human Services in 2023. This has increased the adoption of contraceptive options, with CDC data showing that 65.3% of women aged 15-49 used contraception in 2022, including oral pills (14.0%), implants (4.1%), and intrauterine devices (IUDs) (8.4%).
 

Affordable Care Act (ACA) mandates and state-level regulations ensure coverage for FDA-approved contraceptives without out-of-pocket costs. Such policies have expanded accessibility, especially among lower-income groups and adolescents. This regulatory support continues to be a major growth driver for contraceptive adoption in the U.S.
 

Moreover, innovations such as long-acting reversible contraceptives (LARCs), hormone-free devices, and improved delivery methods have enhanced user convenience and reduced side effects. These product improvements appeal to women seeking both safety and long-term efficacy. The availability of diverse options is expanding overall market penetration.
 

U.S. Contraceptives Market Trends

The market is witnessing significant growth, driven by the growing demand for hormone-free and natural options, shift toward long-acting reversible contraceptives (LARCs), increasing male contraceptive research and awareness, and rising acceptance of emergency contraception, among other factors are collectively boosting the industry growth.
 

• The demand for IUDs and implants is increasing due to their long-term effectiveness, convenience, and minimal user intervention requirements compared to daily contraceptive pills. According to the Centers for Disease Control and Prevention (CDC), the use of long-acting reversible contraceptives (LARCs) among women aged 15-49 increased from 10.3% in 2021 to 11.8% in 2023.
   
• The World Health Organization (WHO) reported that global IUD usage grew by 15% between 2022 and 2024, with implant adoption rates rising by 12% during the same period. Healthcare providers increasingly recommend these LARCs, especially for young women and adolescents, which has reduced the dependence on short-term contraceptive methods such as condoms and oral pills. The National Survey of Family Growth data shows that LARC use among women aged 15-24 reached 16.2% in 2023, up from 13.7% in 2021.
   
• Moreover, online platforms and telehealth providers are making contraceptives more accessible by offering virtual consultations and doorstep delivery. Apps and subscription-based models simplify prescription renewals and ensure continuous access. This digital shift is especially appealing to younger, tech-savvy consumers seeking privacy and convenience.
   
• Further, emergency contraceptive pills are becoming more mainstream due to increasing awareness and availability through retail pharmacies and e-commerce platforms. Younger women are particularly driving demand, valuing the option as a backup method. This acceptance reflects changing attitudes toward reproductive autonomy and convenience-driven choices. Thus, the aforementioned factors are expected to drive the market growth positively.
   

U.S. Contraceptives Market Analysis

The U.S. contraceptives market was valued at USD 6.5 billion in 2021. The market size reached USD 7 billion in 2023, from USD 6.9 billion in 2022.
 

Based on the product, the U.S. contraceptives market is segmented into devices and drugs. The devices segment is further bifurcated into condoms, intra-uterine devices, vaginal rings, subdermal implants, diaphragms, and contraceptive sponges. The drugs segment is further divided into oral contraceptive pills, injectable contraceptives, and topical contraceptives. The devices segment has asserted its dominance in the market by securing a significant market share of 71.3% in 2024 owing to the strong insurance coverage and reimbursement policies, alongside increasing physician preference for IUDs and implants as first-line options for effective, long-term contraception.
 

The segment is expected to exceed USD 10.5 billion by 2034, growing at a CAGR of 7.4% during the forecast period. On the other hand, drugs segment is expected to grow with a CAGR of 3.9%. The growth of this segment can be attributed to the expanding access through telehealth and e-pharmacies, along with rising demand for emergency contraceptives amid greater awareness and time-sensitive availability.
 

• The devices segment continues to dominate the market. IUDs and implants are gaining popularity due to their high efficacy (over 99%), long duration of action, and reduced need for daily compliance compared to pills. Physicians increasingly recommend LARCs for women seeking hassle-free and reliable options. The strong endorsements from organizations like the CDC and ACOG further strengthen confidence and adoption. This trend is a major growth driver for device-based contraceptives.
   
• Continuous research and development has led to hormone-free IUDs, smaller and easier-to-insert devices, and implants with fewer side effects. Vaginal rings offering multi-month coverage are also expanding consumer choices. These innovations enhance safety, user comfort, and acceptance, addressing concerns related to pain, side effects, and insertion procedures.
   
• Additionally, unintended pregnancies remain a public health challenge in the U.S., and devices like IUDs and implants are being promoted as the most effective preventive solutions. Healthcare providers and public health organizations emphasize their role in reducing abortion rates and improving maternal health outcomes. This growing focus has positioned devices as a cornerstone of family planning strategies.
   
• The drugs segment was valued at USD 2.1 billion in 2024 and expected to grow during the forecast period. The segmental growth is driven by broadening access through telehealth platforms and online pharmacies, which make oral pills, injectables, and emergency contraception more convenient and discreet for users. The recent FDA approval of over-the-counter (OTC) oral contraceptives is expected to significantly expand the consumer base by removing prescription barriers.
   
• Additionally, rising awareness about emergency contraception and its time-sensitive benefits has boosted demand, particularly among younger women. Pharmaceutical innovation, combined with increasing insurance coverage and public health campaigns, further strengthens the adoption of contraceptive drugs across diverse demographics.
   

Based on age group, the U.S. contraceptives market is segmented as 15 - 44 years and above 44 years. The 15 - 44 years segment dominated the market in 2024 accounting for USD 6.7 billion and is anticipated to grow at a CAGR of 6.6% during the forecast period.
 

• The 15-44 age group represents women in their prime reproductive years, making them the largest user segment for contraceptives. With active sexual lives and varying family planning needs, this demographic drives consistent demand for both short-term and long-acting contraceptives. Their contraceptive choices directly influence market growth, as they account for the majority of product consumption.
   
• Extensive sex education programs, public health campaigns, and digital awareness initiatives have made younger adults more informed about contraceptive options. Women in this age bracket actively seek safe, effective methods to avoid unintended pregnancies and plan families on their own terms. This awareness significantly boosts adoption across oral pills, devices, and emergency contraceptives.
   
• Additionally, many women in the U.S. are postponing marriage and childbirth to pursue higher education and career opportunities. As a result, demand for contraceptives especially long-acting reversible contraceptives (LARCs) has increased to support lifestyle choices without compromising reproductive autonomy. This social shift is a strong growth driver for the market in this age group.
   
• The above 44 years segment was valued at USD 620 million in 2024 and expected to grow during the forecast period. The growth of the segment is driven by the need for continued pregnancy prevention during perimenopause, as fertility persists until menopause is confirmed. Physicians often recommend safe, low-risk options such as copper IUDs or barrier methods to avoid complications linked with hormonal therapies in older age.
   
• Moreover, many women in this age group use contraceptives for additional health benefits, including management of heavy menstrual bleeding, cycle regulation, and lowering risks of endometrial and ovarian conditions. Increasing awareness, coupled with physician counseling and insurance coverage for contraceptive care, supports steady adoption in this demographic, thereby driving this segment's growth in the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channel, the U.S. contraceptives market is classified into retail pharmacies, hospital pharmacies, online channels, and other distribution channels. The retail pharmacies segment dominated the market with a revenue share of 44.7% in 2024 driven by widespread accessibility, convenience, trusted pharmacist guidance, and immediate product availability, making it the primary choice for contraceptive purchases in the U.S.
 

• The top three distribution channel segments account for over 94.4% of the total market value. The retail pharmacies segment holds the biggest portion since its extensive accessibility and consumer trust. Retail pharmacies are widely available in both urban and rural areas that ensures individuals have convenient and immediate access to contraceptive products without any delays.
   
• The segment benefits via the strong presence of established pharmacy chains such as CVS, Walgreens, also Walmart. The chains provide a broad array of birth control like birth control pills, condoms, and morning after pills. Consumers also rely on licensed pharmacists, and they guide and do crucially educate individuals about proper usage and also available options so strengthening confidence when they then purchase. Retail pharmacies are a choice that is cost-effective and reliable because insurance coverage for prescriptions drives traffic to them. Retail pharmacies do get traffic from insurance coverage.
   
• That retail pharmacies combine convenience, accessibility, professional consultation, plus trusted products makes them the leading distribution channel in the U.S. contraceptives market.
   
• The hospital pharmacies segment has captured the second position in the end-use segment and is expected to grow at a CAGR of 6.1%. The segment is driven by the growing demand for prescription-based contraceptives and the increasing preference for reliable, professional guidance from healthcare providers. Hospitals serve as trusted points of care, ensuring the safe dispensation of advanced contraceptives such as intrauterine devices, implants, and hormonal pills.
   
• Rising awareness of family planning, coupled with the integration of reproductive health services within hospital settings, supports higher adoption. Moreover, the availability of comprehensive counseling, better monitoring, and immediate access to specialized contraceptive methods positions hospital pharmacies as a critical and steadily growing distribution channel in the market.
   
• The online channels segment was valued at USD 1.4 billion and is expected to witness a steady growth in the forecast period. Expanding e-commerce platforms, subscription-based deliveries, and telehealth services are making contraceptives more accessible. Rising internet penetration, competitive pricing, wider product choices, and doorstep delivery further support adoption, while younger, tech-savvy consumers increasingly turn to online platforms for reliable and confidential access to contraceptive products.
   

East North Central Contraceptives Market

The East North Central contraceptives market accounted for USD 1.2 billion market revenue in 2024 and is anticipated to grow at CAGR of 6.1% between 2025 - 2034 period.
 

• The zone experiences relatively higher birth and teen pregnancy rates compared to national averages, creating a strong need for effective family planning solutions. Rising awareness of reproductive health, fueled by both state-led initiatives and non-governmental programs, is encouraging adoption of contraceptives.
   
• Expanding healthcare coverage under Medicaid and state-specific women’s health programs is improving accessibility to a range of modern contraceptives, including oral pills, implants, intrauterine devices (IUDs), and condoms. The growing presence of retail pharmacies and clinics across urban and semi-urban areas, alongside emerging telehealth and online pharmacy services, is further supporting distribution and availability.
   
• Cultural shifts such as women participating more in the workforce and attitudes changing toward family planning and childbearing delays are also contributing to market expansion. For federal funding initiatives, it is demand that is increasing. They are aimed at a reduction in maternal mortality as well as at addressing public health concerns that relate to unintended pregnancies.
   
• The East North Central zone is positioned as a promising U.S. contraceptives market growth pocket because of these drivers.
   

West South-Central Contraceptives Market
 

West South-Central contraceptives market accounted for USD 918.2 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• This zone, has a large and growing population base with diverse demographics, fueling rising demand for contraceptive products and services. Increased awareness with regard to reproductive health, with family planning, and with prevention of unintended pregnancies is driving more adoption because public health campaigns and non-profit initiatives support that. Major urban centers for example Houston, Dallas, and New Orleans are present and allow better access to healthcare infrastructure. Modern contraceptives are widely available because this infrastructure includes retail as well as hospital pharmacies, clinics, and telehealth platforms.
   
• Furthermore, the region’s relatively high teenage pregnancy rates and ongoing concerns around maternal health outcomes are encouraging government bodies and local health organizations to strengthen family planning programs. The rising influence of women in the workforce, coupled with shifting socio-cultural attitudes toward delayed parenthood and smaller family sizes, also contributes significantly to market expansion.
   
• In addition, expanding online channels and subscription-based contraceptive delivery services are improving access in both urban and rural areas. Collectively, these factors are expected to sustain strong growth in the West South-Central contraceptives market.
   

South Atlantic Contraceptives Market
 

The South Atlantic contraceptives market is anticipated to grow at the highest CAGR of 6.9% during the analysis timeframe.
 

• A major driver is the region’s large and diverse population base, where rising awareness of family planning and reproductive health has strengthened the adoption of contraceptive methods. High urbanization rates and an increasing proportion of younger, sexually active populations are fueling greater demand for accessible and reliable contraceptive solutions.
   
• Expanding healthcare infrastructure, coupled with strong support from public health programs and initiatives by organizations like Planned Parenthood, are improving access to a broad range of contraceptives, including oral pills, condoms, intrauterine devices (IUDs), and injectables. Furthermore, the region is witnessing a significant rise in women’s workforce participation, leading to changing lifestyles and increased focus on planned parenthood and delayed pregnancies.
   
• Retail pharmacies, clinics, and online platforms play a crucial role in ensuring availability and convenience, thereby boosting market penetration. Supportive government policies aimed at reducing unintended pregnancies and improving maternal health outcomes further contribute to the market’s robust growth outlook, positioning the South Atlantic as a key growth hub.
   

U.S. Contraceptives Market Share

The market presents a competitive in nature landscape, characterized by the presence of both global leaders and numerous regional players. Key players such as Bayer, Church & Dwight, Cooper, Organon, and Pfizer collectively accounts for 57% of the total market share, leveraging their strong product portfolios, global distribution networks, and focus on product innovation.
 

The top companies collectively hold over half of the market share, driven by their extensive product portfolios spanning oral contraceptives, condoms, intrauterine devices, and emergency contraceptives. These leaders also benefit from established brand recognition, strong physician and consumer trust, and large-scale distribution networks across retail pharmacies, hospital pharmacies, and online channels. Their ability to invest in research and development enables them to introduce innovative products, such as hormonal IUDs, long-acting reversible contraceptives (LARCs), and advanced formulations with fewer side effects, which further strengthens their market positioning.
 

Meanwhile, regional players contribute to market dynamism by offering cost-effective alternatives and catering to specific demographic segments, particularly in underserved areas. The competitive environment is further shaped by strategic initiatives such as mergers, acquisitions, partnerships, and expansion into e-commerce platforms, enabling companies to enhance accessibility and consumer reach.
 

Overall, the U.S. contraceptives market’s share distribution reflects a balance between global leaders driving innovation and regional players fostering affordability and accessibility, creating a diverse yet growth-oriented competitive landscape.
 

U.S. Contraceptives Market Companies

Few of the prominent players operating in the U.S. contraceptives industry include:
 

• Agile Therapeutics
• Bayer
• Church & Dwight
• CooperSurgical
• Evofem Biosciences
• HRA Pharma
• Johnson & Johnson
• LifeStyles Healthcare
• Mayer Laboratories
• Meril Life Sciences
• Organon
• Perrigo Company
• Pfizer
• Pregna International
• Reckitt
  
   
• Bayer

Bayer’s USP in the contraceptives market lies in its leadership in hormonal contraceptives, particularly oral pills and intrauterine devices (IUDs). With strong clinical validation, global reach, and continuous innovation, Bayer positions itself as a trusted provider of effective, safe, and long-acting contraceptive solutions for diverse patient needs.
 

• Church & Dwight

Church & Dwight differentiates itself with its well-recognized Trojan brand, dominating the condom segment in the U.S. Its USP lies in strong brand loyalty, wide retail availability, product variety, and emphasis on quality and innovation, making it a household name in barrier contraceptive solutions.
 

• CooperSurgical

CooperSurgical’s USP stems from its strong expertise in women’s health and fertility management, offering advanced intrauterine devices (IUDs) and contraceptive technologies. Its focus on clinical efficacy, physician partnerships, and global presence ensures it remains a key provider of long-term, reliable, and medically integrated contraceptive solutions worldwide.
 

U.S. Contraceptives Industry News:

• In March 2024, Perrigo Company plc announced the U.S. availability of Opill, its oral contraceptive pill, now offered without a prescription. Additionally, Opill is accessible through online sales on the company’s website, marking a milestone in improving consumer access and convenience within the contraceptives market.
   
• In October 2023, Xiromed LLC launched its new vaginal ring, EnilloRing, in the U.S. market as a generic version of NuvaRing. The introduction of EnilloRing enables Xiromed to address the growing demand for affordable contraceptive options, expanding its presence and accessibility within the U.S. contraceptives landscape.
   
• In April 2023, Veru Inc. entered into a distribution agreement with Afaxys Group Services, LLC (AGS) to expand access to the FC2 Female Condom. Through AGS’s Group Purchasing Organization (GPO), the partnership aims to serve over 31 million individuals relying on public health and community centers, enhancing contraceptive availability for both women and men.
   
• In March 2023, NEXT Life Sciences, Inc., a medical device company, introduced Plan A, a new reversible male contraceptive. Designed as a safe and effective birth control solution for men, Plan A highlights innovation in male-focused contraceptives, expanding choices beyond traditional female-centered methods.
   
• In February 2021, Amneal Pharmaceuticals, Inc. received FDA approval for its generic version of Ortho Evra contraceptive patch, prescribed for pregnancy prevention. This approval strengthens Amneal’s contraceptives portfolio by offering a cost-effective alternative to branded products and reinforces its competitive positioning in the market.
   

The U.S. contraceptives market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices                  
  • Condoms      
    • Male
    • Female
  • Intra-uterine devices         
    • Hormonal IUD
    • Copper IUD
  • Vaginal rings 
  • Subdermal implants 
  • Diaphragms  
  • Contraceptive sponges        
• Drugs          
  • Oral contraceptive pills      
  • Injectable contraceptives   
  • Topical contraceptives         

Market, By Age Group

• 15 - 44 years
• Above 44 years

Market, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels